We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

ACI with Chondro-Gide

Autologous Chondrocyte Implantation (ACI) is a technique for the treatment of large isolated cartilage defects. A small sample of cartilage is harvested from a non-weight-bearing part of the joint during arthroscopy. In a laboratory the chondrocytes are dissolved away of the tissue composite and multiplied in culture dishes.

After a cultivation period of 3 to 4 weeks a cell count of approx. 1 million cells/cm2 is achieved, depending on the size of the defect. In a second surgical procedure, the Chondro-Gide® is inoculated with the cells and fitted into the defect. Under the physicochemical effects of the articular milieu, the cells, accompanied by a carefully-adapted rehabilitation programme, form high-grade regenerated cartilage, which has almost 90% of the biomechanical properties of healthy articular cartilage (Steinwachs, 2008).

Indications

  • Chondral & osteochondral lesions grade III-IV (Outerbridge classification)
  • Osteochondral defects in conjunction with bone-grafting
  • Focal, traumatic defects
  • Defect size 6.0 - 12.0 cm2
  • Patients aged between 18 - 55 years


Advantages in the use of Chondro-Gide® versus periosteum

  • No need for a second operative site to remove periosteum
  • Reduced risk of hypertrophy
  • Reduced risk of delamination
  • Shorter operative time
  • Easy handling
  • Consistent quality of matrix

Further information about Chondro-Gide® and ACI is available from your Geistlich Surgery representative.

 

Dr. Sanja Saftic
International Product Manager